Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05159440
Other study ID # TORL2307MAB-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 20, 2022
Est. completion date December 15, 2025

Study information

Verified date December 2023
Source TORL Biotherapeutics, LLC
Contact Stephen Letrent, PharmD, PhD
Phone 858-342-6652
Email stephen.letrent@torlbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 15, 2025
Est. primary completion date December 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Advanced solid tumor - Measurable disease, per RECIST v1.1 - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Adequate organ function Exclusion Criteria: - Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade =1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements - Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-2-307-MAB - Progressive or symptomatic brain metastases - Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection - History of significant cardiac disease - History of myelodysplastic syndrome (MDS) or AML - History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded - If female, is pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TORL-2-307-MAB
monoclonal antibody

Locations

Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
United States Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana
United States Providence St. Jude Medical Center Fullerton California
United States UCLA - JCCC Clinical Research Unit Los Angeles California
United States Torrance Memorial Medical Torrance California

Sponsors (2)

Lead Sponsor Collaborator
TORL Biotherapeutics, LLC Translational Research in Oncology

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of adverse events and serious adverse events Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0 up to 2 years
Primary Maximum Tolerated Dose (MTD) Highest administered dose with < 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants 28 Days
Primary Recommended Phase 2 Dose (RP2D) Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data up to 2 years
Secondary Objective Response Rate (ORR) Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1 up to 2 years
Secondary Duration of Response (DOR) Time from CR or PR to objective disease progression or death to any cause up to 2 years
Secondary Progression Free Survival (PFS) PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause up to 2 years
Secondary Time to Response (TTR) Time from start of treatment to complete response or partial response up to 2 years
Secondary 1 Year Overall Survival (1YOS) Proportion of participants alive at 1 year from the start of treatment to death from any cause 1 year
Secondary 2 Year Overall Survival (2YOS) Proportion of participants alive at 2 years from the start of treatment to death from any cause 2 years
Secondary Number of anti-drug antibody (ADA) Positive Participants Immunogenicity will be measured by the number of participants that are ADA positive. up to 2 years
Secondary Maximum Serum Concentration of TORL-2-307-MAB (Cmax) PK assessment 21 days
Secondary Minimum Serum Concentration of TORL-2-307-MAB (Cmin) PK assessment 21 days
Secondary Maximum Serum Concentration of TORL-2-307-MAB at Steady State (Cmax,ss) PK assessment 63 days
Secondary Minimum Serum Concentration of TORL-2-307-MAB at Steady State (Cmin,ss) PK assessment 63 days
Secondary Time of Maximum Serum Concentration of TORL-2-307-MAB (Tmax) PK assessment 21 days
Secondary Time of Minimum Serum Concentration of TORL-2-307-MAB (Tmin) PK Assessment 21 days
Secondary Time of Minimum Serum Concentration of TORL-2-307-MAB at Steady State (Tmin,ss) PK Assessment 63 days
Secondary Terminal Half-life (t1/2) of Serum TORL-2-307-MAB PK Assessment 63 days
Secondary Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23 PK Assessment 21 days
Secondary Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23 PK Assessment 63 days
Secondary Apparent volume of distribution during the terminal phase (Vz) of TORL-2-307-MAB PK Assessment 63 days
Secondary Clearance (CL) of TORL-2-307-MAB PK Assessment 63 days
Secondary Accumulation ratio (Rac) of TORL-2-307-MAB PK Assessment 63 days
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2